Transfusion-Associated Graft-vs- Host Disease (TA-GVHD): Further Reading

Note: Canadian Blood Services offers no endorsement of and assumes no liability for the currency, accuracy, or availability of any information on these sites.

1. Food and Drug Administration. Gamma Irradiation of Blood Products. CBER, FDA 1993.
2. Guidelines for Irradiation of Blood and Blood Components. New York State Council on Human Blood and Transfusion Services. June 9, 1993.
3. Luban NL. Irradiation for neonatal and pediatric transfusion in: Herman JH, Manno CS. Pediatric Transfusion Therapy. Bethesda MD: AABB Press; 2002: 147-169.
4. Luban NL. Prevention of transfusion-associated graft versus host disease by inactivation of T cells in platelet components. Semin Hematol 2001 Oct;38 (4 Suppl 11):34-45. [ Medline ].
5. McMilin KD, Johnson RL. HLA homozygosity and the risk of related-donor transfusion-associated graft versus host disease. Transfus Med Rev 1993 Jan; 7(1):37-41. [ Medline ].
6. Nollet KE, Holland PV. Toward a coalition against transfusion-associated GVHD. Transfusion 2004; 43 (12):1655-7. [ Full Text ] [ Medline ]
7. Triulzi Darrell J. Transfusion Support in Solid-Organ Transplantation. Institute for Transfusion Medicine. Transfusion Medicine Update. April 2001.
8. Webb IJ, Anderson KC. Transfusion-associated graft versus host disease. In: Popovsky MA, ed. Transfusion reactions, 2nd ed. Bethesda, MD: AABB Press; 2001. 171-82.
9. Wong ECC, Irradiated Products in: Hillyer CD, Strauss RG, Luban NLC. Handbook of Pediatric Medicine. San Diego CA: Elsevier Academic Press; 2004: 101-112.